ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 沪
等待开盘 05-21 09:30:00 美东时间
0.0056
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 总市值 1.87万
- 52周最高 0.1498
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 总股本 334.74万
- 历史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
Artelo Biosciences Ends ATM Offering, Shifts Financing Strategy
An announcement from Artelo Biosciences ( ($ARTL) ) is now available. On May 11...
05-16 05:28
Artelo Biosciences shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Artelo Biosciences shares are trading lower after the company reported worse-th...
05-15 23:16
Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share
05-15 04:56
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Artelo Biosciences provided a business update for Q1 2026, highlighting progress in its clinical pipeline and financial strength. ART26.12, a potential first-in-class analgesic, is advancing through Phase 1 studies with promising preclinical data. ART27.13 is being explored for additional indications, including as a GLP-1 companion therapy and in a fully funded glaucoma study. The company strengthened its balance sheet with $10.3 million in cash ...
05-14 20:05
Artelo Biosciences Files Prospectus For Offering $75M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1621221/000164033426000820/artl_s3.htm
05-05 04:55
Artelo Biosciences Collaborates With ScienceMachine Over Development Of Its Fatty Acid-Binding Protein 5 Inhibitor Platform
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
04-28 20:26
What's Behind The Rise In Artelo Biosciences Stock?
Artelo Biosciences, Inc. (NASDAQ:ARTL) shares jumped on Monday after the company announced the publication of a peer‑reviewed article highlighting FABP5 as a therapeutic target for pain.
04-21 00:06
Artelo Biosciences Announces Publication Of Peer‑Reviewed Article On FABP5 As Therapeutic Target For Pain Management In European Journal Of Pain
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This YearPhase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to
04-20 19:52
Artelo advances ART26.12 into multiple ascending dose trial after Phase 1 safety data
Artelo advances ART26.12 into multiple ascending dose trial after Phase 1 safety data Artelo Biosciences announced peer-reviewed publication in European Journal of Pain supporting FABP5 inhibitor ART26.12 as potential first-in-class, non-opioid pain treatment. Publication presented preclinical evide
04-20 19:50
